PAX2、PAX8 和 PR 与伴有子宫内膜异位症的卵巢浆液黏液性交界性肿瘤相关。
PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
机构信息
Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University School of Medicine, Goyang, Korea.
Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.
出版信息
J Ovarian Res. 2022 Apr 6;15(1):41. doi: 10.1186/s13048-022-00975-5.
BACKGROUND
Ovarian "seromucinous carcinoma" has been recently removed in 2020 5 Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while "seromucinous borderline tumor" remains and exists as a distinct entity. Both diseases may be considered as no more same lineage. However, ovarian seromucinous borderline tumor (SMBT) is also one of the endometriosis-related neoplasm of ovary similar to endometrioid tumor, featuring that about 50% of ovarian SMBTs combine endometriosis. The present study was aimed to investigate whether the ovarian SMBTs are different in clinical features and molecular patterns, according to the presence of combined endometriosis.
RESULTS
There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups.
CONCLUSIONS
Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.
背景
卵巢“黏液性浆液性癌”在 2020 年第五版世界卫生组织女性生殖器官肿瘤分类中被删除，被认为是具有黏液分化的子宫内膜样癌的一种亚型，而“黏液性浆液性交界性肿瘤”仍然存在，是一种独特的实体。这两种疾病可能不再属于同一谱系。然而，卵巢黏液性浆液性交界性肿瘤（SMBT）也是与子宫内膜样肿瘤相似的卵巢子宫内膜异位症相关肿瘤之一，约有 50%的卵巢 SMBT 合并子宫内膜异位症。本研究旨在探讨卵巢 SMBT 是否因合并子宫内膜异位症而在临床特征和分子模式上存在差异。
结果
两组间的临床发现无统计学差异。两组间的妊娠结局和复发也无显著差异。在免疫组织化学模式中，合并子宫内膜异位症的卵巢 SMBT 和不合并子宫内膜异位症的卵巢 SMBT 之间，PAX2 和 PAX8 的表达存在统计学差异（P=0.016，P<0.001）。只有少数合并子宫内膜异位症的卵巢 SMBT 表达 PAX2，相反，大多数病例表达 PAX8。与不合并子宫内膜异位症的卵巢 SMBT 相比，合并子宫内膜异位症的卵巢 SMBT 的 PR 阳性表达更为显著（P=0.018），尽管 ER 阳性表达无差异。两组间 WT1、CK20 和 CDX2 的表达无统计学差异。
结论
合并子宫内膜异位症的卵巢 SMBT 在临床上与不合并子宫内膜异位症的卵巢 SMBT 无差异。然而，两组间的分子模式不同，合并子宫内膜异位症的卵巢 SMBT 与子宫内膜样肿瘤类型接近，而不合并子宫内膜异位症的 SMBT 则不同。此外，需要对浆液性交界性肿瘤和子宫内膜样交界性肿瘤进行直接比较研究，并进行基因谱研究以证明它们之间的关系。
Zotero 插件